case_images: PMC10864460_01
case_images: (A) endometrioma 6cm at the 0-month of dienogest use. (B) decreased size of endometrioma to 3cm with thin wall at the 24-months of dienogest use. (C) increased size of endometrioma to 6cm with mural part suspect malignancy at the 48-months of dienogest use. (D) endometrioma had increased to 8cm with excrescences 3cm and intra-tumor flow at the 51-months of dienogest use.
case_images: fonc-14-1338472-g001.jpg
case_images: PMC10864460_01_fonc-14-1338472-g001.jpg
case_images: f1
case_images: She suffered from acute abdominal pain when the endometrioma had increased to 6 cm ( Figure 1A ). The size of endometrioma dropped to 3 cm ( Figure 1B ) at the 24-months of dienogest use. However, at the 48-months of dienogest use, her endometrioma enlarged to 5 cm with a 1.3 cm mural nodule without internal flow ( Figure 1C ). Three months later (at the 51-months of dienogest use), her endometrioma further enlarged to 8 cm, and with the presence of 3 cm excrescence showing intra-tumor flow ( Figure 1D ).